CO6690744A2 - Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa - Google Patents

Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa

Info

Publication number
CO6690744A2
CO6690744A2 CO13019325A CO13019325A CO6690744A2 CO 6690744 A2 CO6690744 A2 CO 6690744A2 CO 13019325 A CO13019325 A CO 13019325A CO 13019325 A CO13019325 A CO 13019325A CO 6690744 A2 CO6690744 A2 CO 6690744A2
Authority
CO
Colombia
Prior art keywords
dry powder
powder formulation
phosphodiesterase inhibitor
relates
formulation
Prior art date
Application number
CO13019325A
Other languages
English (en)
Inventor
Daniela Cocconi
Francesca Schiaretti
Roberto Bilzi
Original Assignee
Chesi Farmaceutici S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chesi Farmaceutici S P A filed Critical Chesi Farmaceutici S P A
Publication of CO6690744A2 publication Critical patent/CO6690744A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se relaciona con una formulación farmacéutica en la forma de un polvo seco inhalable que comprende partículas de un inhibidor de fosfodiesterasa-4 como ingrediente activo. La invención también se relaciona con el proceso para preparar la formulación y con su uso en la prevención y/o el tratamiento de una enfermedad respiratoria tal como asma y EPOC.La presente invención se relaciona con Una formulación de polvo seco inhalable, CARACTERIZADA PORQUE comprende, como ingrediente activo, partículas micronizadas de un compuesto de la fórmula general (I) como el enantiómero (-),
CO13019325A 2010-08-03 2013-02-01 Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa CO6690744A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03

Publications (1)

Publication Number Publication Date
CO6690744A2 true CO6690744A2 (es) 2013-06-17

Family

ID=43262631

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13019325A CO6690744A2 (es) 2010-08-03 2013-02-01 Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa

Country Status (36)

Country Link
US (2) US9132121B2 (es)
EP (2) EP2600830B1 (es)
JP (1) JP6004233B2 (es)
KR (1) KR101805958B1 (es)
CN (2) CN103052379A (es)
AR (1) AR082443A1 (es)
AU (1) AU2011287711B2 (es)
BR (1) BR112013002506A2 (es)
CA (1) CA2807256C (es)
CL (1) CL2013000293A1 (es)
CO (1) CO6690744A2 (es)
CY (1) CY1120605T1 (es)
DK (1) DK2600830T3 (es)
EA (2) EA027692B1 (es)
ES (1) ES2664175T3 (es)
GE (1) GEP20156343B (es)
HR (1) HRP20180717T1 (es)
HU (1) HUE037620T2 (es)
IL (1) IL224517B (es)
LT (1) LT2600830T (es)
MA (1) MA34449B1 (es)
ME (1) ME03022B (es)
MX (1) MX346424B (es)
MY (1) MY179703A (es)
NO (1) NO2600830T3 (es)
NZ (1) NZ606548A (es)
PE (2) PE20130601A1 (es)
PL (1) PL2600830T3 (es)
PT (1) PT2600830T (es)
RS (1) RS57061B1 (es)
SG (1) SG187258A1 (es)
SI (1) SI2600830T1 (es)
TR (1) TR201807012T4 (es)
UA (1) UA112296C2 (es)
WO (1) WO2012016889A2 (es)
ZA (1) ZA201300870B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CA2807406C (en) 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
EP3060551B1 (en) 2013-10-22 2019-09-18 Chiesi Farmaceutici S.p.A. Process for the preparation of a pde4 inhibitor
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
EA201692456A1 (ru) * 2014-07-09 2017-08-31 Арвен Иладж Санайи Ве Тиджарет А.Ш. Способ получения составов для ингаляции
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
KR101859750B1 (ko) * 2017-09-13 2018-05-21 제일에스엠피(주) 고정식 열 저장 운반장치
KR101859752B1 (ko) * 2017-09-13 2018-05-21 심원 조립식 열 저장 운반장치
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
WO1999014604A1 (de) 1997-09-16 1999-03-25 Trench Switzerland Ag Spannungsteiler
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
SI1386630T1 (sl) 2002-07-31 2006-10-31 Chiesi Farma Spa Inhalator za prasek
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CN101189210B (zh) * 2005-06-06 2012-06-06 霍夫曼-拉罗奇有限公司 可用作肝肉碱棕榈酰转移酶(l-cpt1)抑制剂的磺酰胺衍生物
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CA2807406C (en) 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP3060551B1 (en) 2013-10-22 2019-09-18 Chiesi Farmaceutici S.p.A. Process for the preparation of a pde4 inhibitor

Also Published As

Publication number Publication date
PL2600830T3 (pl) 2018-08-31
AR082443A1 (es) 2012-12-05
EA201390049A1 (ru) 2013-05-30
KR20130094784A (ko) 2013-08-26
ES2664175T3 (es) 2018-04-18
US9132121B2 (en) 2015-09-15
AU2011287711B2 (en) 2016-10-27
HRP20180717T1 (hr) 2018-07-13
MA34449B1 (fr) 2013-08-01
PE20130601A1 (es) 2013-05-30
JP2013532705A (ja) 2013-08-19
EP2600830B1 (en) 2018-02-21
PE20171256A1 (es) 2017-08-28
KR101805958B1 (ko) 2017-12-07
WO2012016889A3 (en) 2012-04-19
EA024922B1 (ru) 2016-11-30
WO2012016889A2 (en) 2012-02-09
GEP20156343B (en) 2015-08-10
SI2600830T1 (en) 2018-05-31
MY179703A (en) 2020-11-11
EA027692B1 (ru) 2017-08-31
IL224517B (en) 2018-04-30
TR201807012T4 (tr) 2018-06-21
EP2600830A2 (en) 2013-06-12
ME03022B (me) 2018-10-20
CA2807256A1 (en) 2012-02-09
NO2600830T3 (es) 2018-07-21
ZA201300870B (en) 2014-04-30
MX346424B (es) 2017-03-21
HUE037620T2 (hu) 2018-09-28
EP3246016A1 (en) 2017-11-22
CA2807256C (en) 2018-08-28
LT2600830T (lt) 2018-04-10
US20150342936A1 (en) 2015-12-03
US9308200B2 (en) 2016-04-12
US20120031403A1 (en) 2012-02-09
EA201690541A1 (ru) 2016-07-29
UA112296C2 (uk) 2016-08-25
DK2600830T3 (en) 2018-03-12
AU2011287711A1 (en) 2013-02-21
RS57061B1 (sr) 2018-06-29
MX2013001172A (es) 2013-03-07
JP6004233B2 (ja) 2016-10-05
CN106890165A (zh) 2017-06-27
CY1120605T1 (el) 2019-12-11
BR112013002506A2 (pt) 2016-05-31
SG187258A1 (en) 2013-03-28
NZ606548A (en) 2015-02-27
CN103052379A (zh) 2013-04-17
PT2600830T (pt) 2018-04-02
CL2013000293A1 (es) 2013-05-03

Similar Documents

Publication Publication Date Title
CO6690744A2 (es) Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa
GT201400016A (es) Indazoles
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
WO2014097151A3 (en) Autotaxin inhibitors
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CL2011000425A1 (es) Compuestos derivados de heteroariloxi amidas del acido benzoico sustituido, inhibidores de map-quinasa p38; procedimiento de preparacion de los compuestos; composicion farmaceutica; procedimiento para preparar dicha composicion; y uso en el tratamiento de enfermedades de las vias aereas como epoc y asma.
MX336381B (es) Boronatos como inhibidores de arginasa.
CL2014000113A1 (es) Compuestos derivados de quinolinas sustituidas; formulacion farmaceutica que los contiene; y su uso para el tratamiento de una enfermedad que se puede tratar mediante la inhibicion de la enzima syk, tales como rinitis alergica, asma, epoc, bronquitis, lupus eritematoso, esclerosis multiple, osteoporosis, osteopenia y arterioesclerosis.
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
PE20151414A1 (es) NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
IN2014DN06869A (es)
TN2013000529A1 (en) Trpm8 antagonists and their use in treatments
IN2014DN09347A (es)
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2799082A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).